Home > References > Treatment Recommendations > Neonates/Paediatric & Adult Patients > Respiratory

Respiratory

  1. Woodhead M, Blasi F, Ewig S, et al.  Guidelines for the management of adult lower respiratory tract infections - full version.  Clin Microbiol Infect 2011;17(suppl 6):E1-59.
  2. Woodhead M, Blasi F, Ewig S, et al.  Guidelines for the management of adult lower respiratory tract infections - summary.  Clin Microbiol Infect 2011;17(suppl 6):1-24.   

Pharyngitis

  1. Adam D, Scholz H, Helmerking M.  Short-course antibiotic treatment of 4782 culture-proven cases of group A Streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae.  J Infect Dis 2000;182:509-16.
  2. Bass JW, Person DA, Chan DS.  Twice-daily oral penicillin for treatment of streptococcal pharyngitis: less is best.  Pediatrics 2000;423-4.
  3. Bisno AL.  Are cephalosporins superior to penicilin for treatment of acute streptococcal pharyngitis?  Clin Infect Dis 2004;38:1535-7.
  4. Bisno AL, Gerber MA, Gwaltney JM, et al.  Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis.  Clin Infect Dis 2002;35:113-25.
  5. Bisno AL, Peter GS, Kaplan EL.  Diagnosis of strep throat in adults:  are clinical criteria really good enough?  Clin Infect Dis 2002;35:126-9.
  6. Brink WR, Rammelkamp CH, Denny FW, et al.  Effect of penicillin and aureomycin on the natural course of streptococcal tonsillitis and pharyngitis. Am J Med 1951;10:300-8.
  7. Brook I.  ß-lactamase-producing bacteria in mixed infections.  Clin Microbiol Infect 2004;10:777-84.
  8. Casey JR, Pichichero ME.  Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis.  Clin Infect Dis 2005;40:1748-55.
  9. Casey JR, Pichichero ME.  Meta-analysis of cephalosporins verus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults.  Clin Infect Dis 2004;38:1526-34.
  10. Casey JR, Pichichero ME.  Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children.  Pediatrics 2004;113:866-82.
  11. Casey JR, Pichichero ME.  Metaanalysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis.  Ped Infect Dis J 2005;24:909-17.
  12. Catanzaro FJ, Stetson CA, Morris AJ, et al.  The role of the streptococcus in the pathogenesis of rheumatic fever. Am J Med 1954;17:749-56.
  13. Centor RM, Witherspoon JM, Dalton HP, et al. The diagnosis of strep throat in adults in the emergency room. Med Dec Making 1981;1:239-46.
  14. Choby BA.  Diagnosis and treatment of streptococcal pharyngitis.  Am Fam Physician 2009;79:383-90.
  15. Cimolai N, Elford RW, Bryan L, et al. Do the b-haemolytic non-group A Streptococci cause pharyngitis? Rev Infect Dis 1988;10:587-601.
  16. Clarridge JE.  The recognition and significance of Arcanobacterium haemolyticum.  Clin Microbiol Newsletter 1989;11:41-5.
  17. Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults:  background.  Ann Intern Med 2001;134:509-17.
  18. Davies HD, Low DE, Schwartz B, et al. Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A Streptococci. Clin Infect Dis 1995;21:1294-6.
  19. Del Mar CB, Glasziou PP, Spinks AB.  Antibiotics for sore throat.  Cochrane Database Syst Rev, Issue 3, 2004.
  20. DKML. Laboratory diagnosis and management of bacterial pharyngitis. 1996;1
  21. Ebell MH, Smith MA, Barry HC, et al.  Does this patient have strep throat?  JAMA 2000;284:2912-8.
  22. El Daher N, Hijazi S, Rawashdeh N, et al.  Immediate vs. delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin V. Pediatr Infect Dis J 1991;10:126-30.
  23. Feder HM, Gerber MA, Randolph MF, et al.  Once-daily therapy for streptococcal pharyngitis with amoxicillin.  Pediatrics 1999;103:47-51.
  24. Fine AM, Nizet V, Mandl KD.  Large-scale validation of the Centor and McIsaac scores to predict group A streptococcal pharyngitis.  Arch Intern Med 2012;172:847-52.
  25. Gerber M, Spadaccini L, Wright L, et al.  Twice daily penicillin in the treatment of streptococcal pharyngitis. Am J Dis Child 1985;139:1145-8.
  26. Gerber MA, Baltimore RS, Eaton CB, et al.  Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis.  Circulation 2009;119:1541-51.
  27. Gerber MA, Randolph MF, Martin NJ, et al.  Community-wide outbreak of group G Streptococcal pharyngitis.  Pediatrics 1991;87:598-603.
  28. Gillespie SH.  Failure of penicillin in Streptococcus pyogenes pharyngeal infection.  Lancet 1998;352:1954-6.
  29. Infectious Diseases and Immunization Committee.  Treatment of group A Streptococcal pharyngitis. Can J Infect Dis 1997;8:17-18.
  30. Jensen JH, Larsen SB. Treatment of recurrent acute tonsillitis with clindamycin: an alternative to tonsillectomy? Clin Otolaryngol 1991;16:498-500.
  31. Lan AJ, Colford Jr JM.  The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis.  Pediatrics 2000;105:e19.
  32. Kociolek LK, Shulman ST.  Pharyngitis.  Ann Intern Med 2012;ITC3:1-16.
  33. McIsaac WJ, White D, Tannenbaum D, et al.  A clinical score to reduce unnecessary antibiotic use in patients with sore throat.  Can Med Assoc J 1998;158:75-83.
  34. Orrling A, Stjernquist-Desatnik A, Schalen C, et al.  Clindamycin in persisting streptococcal pharyngotonsillitis after penicillin treatment.  Scand J Infect Dis 1994;26:535-41.
  35. Parsons WD.  The diagnosis and treatment of streptococcal pharyngitis. Can Fam Physician 1987;33:1445-8.
  36. Peter G.  Streptococcal pharyngitis: current therapy and criteria for evaluation of new agents. Clin Infect Dis 1992;14:S218-23.
  37. Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis:is the difference worth it? Pediatr Infect Dis J 1993;12:268-74.
  38. Pichichero ME, Margolis PA.  A comparison of cephalosporins and penicillins in the treatment of group A beta-haemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial co-pathogenicity. Pediatr Infect Dis J 1991;10:275-81.
  39. Sauve LA, Forrester M, Top KA.  Group A streptococcal (GAS) pharyngitis: A practical guide to diagnosis and treatment.  Paediatr Child Health 2021;26(5):319.
  40. Schwartz B, Marcy SM, Phillips WR, et al.  Pharyngitis – principles of judicious use of antimicrobial agents.  Pediatrics 1998;101:171-3.
  41. Shulman ST, Bisno AL, Clegg HW, et al.  Clinical practice guideline for the diagnosis and management of Group A Streptococcal pharyngitis:  2012 update by the Infectious Diseases Society of America.  Clin Infect Dis 2012;55:e86-102.
  42. Shulman ST, Gerber MA.  So what's wrong with penicillin for strep throat?  Pediatrics 2004;113:1816-9.
  43. Shulman ST, Gerber MA, Tanz RR, et al.  Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994;13:1-7.
  44. Snow S, Mottur-Pilson C, Cooper RJ, et al.  Principles of appropriate antibiotic use for acute pharyngitis in adults.  Ann Intern Med 2001;134:506-8.
  45. Tan JS.  Treatment recommendations for acute pharyngitis.  Curr Treatment Options Infect Dis 2003;5:143-50.
  46. Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group A Streptococci. J Pediatr 1991;119:123-8.
  47. Tanz RR, Shulman ST, Barthel MJ, et al.  Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci.  J Pediatr 1985;106:876-80.
  48. Tanz RR, Shulman ST, Sroka PA, et al.  Lack of influence of beta-lactamase producing flora on recovery of group A streptococci after treatment of acute pharyngitis.  J Pediatr 1990;117:859-63.
  49. Wessels MR.  Streptococcal pharyngitis.  N Engl J Med 2011;364:648-55.  

Jugular Vein Septic Phlebitis

  1. Riordan T.  Human infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's Syndrome.  Clin Micro Rev 2007;20:622-59.

Pertussis (Whooping cough)

  1. Aoyama T, Sunakawa K, Iwata S, et al.  Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin.  J Pediatr 1996;129:761-4
  2. Birkebaek NH, Kristiansen M, Seefeldt T, et al.  Bordetella pertussis and chronic cough in adults.  Clin Infect Dis 1999;29:1239-42.
  3. Capital Health Regional Public Health.  Pertussis.  Communicable Disease Corner 1998;2:1-2.
  4. Health Protection Agency guidelines for the public health management of pertussis 2012.
  5. Hewlett EL, Edwards KM.  Pertussis – not just for kids.  N Engl J Med 2005;352:1215-22.
  6. Mihaljevic F.  Azithromycin in the treatment of pertussis in children:  a pilot study.  ICMAS Abstract 1996; Jan 24-27.
  7. Parkins MD, McNeil SA, Laupland KB.  Routine immunization of adults in Canada:  Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.  Can J Infect Dis Med Microbiol 2009;20:e81-90.
  8. Senzilet LD, Halperin SA, Spika JS, et al.  Pertussis is a frequent cause of prolonged cough illness in adults and adolescents.  Clin Infect Dis 2001:32;1691-7.
  9. Singh M, Lingappan K.  Whooping cough - the current scene.  Chest 2006;130:1547-53.
  10. Tozzi AE, Celentano LP, Ciofi degli Atti, ML, et al.  Diagnosis and management of pertussis.  CMAJ 2005;172:509-15.
  11. Wirsing von Konig CH.  Use of antibiotics in the prevention and treatment of pertussis.  Pediatr Infect Dis J 2005;24:S66-8.

Croup

  1. Alberta Medical Association.  Guideline for the diagnosis and management of croup.  Edmonton (AB):  Toward Optimized Practice;2008.  Available from:  https://www.topalbertadoctors.org/uploads/croup_guideline.pdf
  2. Cherry JD.  Croup.  N Engl J Med 2008;358:384-91.

Otitis Media

  1. AHRQ.  Management of acute otitis media.  Summary, Evidence report/technology assessment:  number 15, June 2000.  Agency for Healthcare Quality and Research (AHRQ), Rockville, MD.  https://www.ahrq.gov/clinic/epcsums/otitisum.htm
  2. American Academy of Family Physicians, American Academy of Otolaryngology-Head and Neck Surgery and American Academy of Pediatrics.  Otitis media with effusion.  Pediatrics 2004;113:1412-29.
  3. American Academy of Pediatrics and American Academy of Family Physicians.  Clinical practice guideline.  Diagnosis and management of acute otitis media.  Pediatrics 2004;113:1451-65.
  4. Anon.  Drugs for treatment of acute otitis media in children.  Med Lett Drugs Ther 1994;36:19-21.
  5. Arrieta A, Arguedas A, Fernandez P, et al.  High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.  Antimicrob Agents Chemother 2003;47:3179-86.
  6. Arrieta A, Singh J.  Management of recurrent and persistent acute otitis media:  new options with familiar antibiotics.  Pediatr Infect Dis J 2004;23:S115-24.
  7. Boucher FD.  The new macrolide antibiotics: use them carefully.  Paediatr Child Health 1997;2:385-6.
  8. Casselbrant ML, Kaleida PH, Rockette HE, et al.  Efficacy of antimicrobial prophylaxis and of tympanostomy tube insertion for prevention of recurrent acute otitis media:  results of a randomized clinical trial.  Pediatr Infect Dis J 1992;11:278-86.
  9. Coker TR, Chan LS, Newberry SJ, et al.  Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children.  JAMA 2010;304:2161-9.
  10. Courter JD, Baker WL, Nowak KS, et al.  Increased clinical failures when treating acute otitis media with macrolides:  a meta-analysis.  Ann Pharmacother 2010;44:471-8.
  11. Craig WA, Andes D.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.  Pediatr Infect Dis J 1996;15:944-8.
  12. Dagan R, Abramson O, Leibovitz E, et al.  Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin.  Ped Infect Dis J 1996;15:980-5.
  13. Dagan R, et al.  Bacteriologic and clinical efficacy of amoxicillin-clavulanate vs azithromycin in acute otitis media. Pediatr Infect Dis J 2000;19:95-104.
  14. Delage G, Dery P, Gold R, et al.  Consensus recommendations for the management of otitis media.  Can J Diagn 1989;6:67-76.
  15. Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-13.
  16. Dowell SF, Butler JC, Giebink GS, et al.  Acute otitis media: management and surveillance in an era of pneumococcal resistance – a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.  Pediatr Infect Dis J 1999;18:1-9.
  17. Dowell SF, Marcy MS, Phillips WR, et al.  Otitis media - principles of judicious use of antimicrobial agents.  Pediatrics 1998;101:165-71.
  18. Forgie S, Zhanel G, Robinson J.  Management of acute otitis media.  Paediatr Child Health 2009;14:ID 2009-01.
  19. Froom J, Culpepper L, DeMelker RA, et al.  Antimicrobials for acute otitis media?  A review from the International Primary Care Network.  Brit Med J 1997;315:98-102.
  20. Glasziou PP, Del Mar CB, Sanders SL, et al.  Antibiotics for acute otitis media in children (Cochrane Review).  In:  The Cochrane Library, Issue 3, 2004. Chichester, UK:  John Wiley & Sons, Ltd.
  21. Green SM, Rothrock SG.  Single-dose intramuscular ceftriaxone for acute otitis media in children.  Pediatrics 1993;91:23-30.
  22. Harrison CJ.  Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy.  Pediatr Infect Dis J 1997;16:S12-6.
  23. Hedrick JA, Sher LD, Schwartz RH, et al.  Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media.  Clin Therapeutics 2001;23:193-204.
  24. Hoberman A, Paradise JL, Rockette HE, et al.  Shortened antimicrobial treatment for acute otitis media in young children.  N Engl J Med 2016;375:2446-56.
  25. Hoberman A, Paradise JL, Rockette HE, et al.  Treatment of acute otitis media in children under 2 years of age.  N Engl J Med 2011;364:105-15.
  26. Kenna MA.  Otitis media and the new guidelines.  J Otolaryngology 2005;34(suppl 1):S24-32.
  27. Klein JO.  Is acute otitis media a treatable disease?  N Engl J Med 2011;364:168-9.
  28. Klein JO.  Microbiologic efficacy of antibacterial drugs for acute otitis media.  Pediatr Infect Dis J 1998;12:973-5.
  29. Le Saux N, Gaboury I, Baird M, et al.  A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age.  CMAJ 2005;172:335-41.
  30. Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. Ped Infect Dis J 2001;20:260-4.
  31. Leibovitz E, et al.  Bacteriologic efficacy of a three-day intramuscular ceftriaxone regimen in nonresponsive acute otitis media.  Ped Infect Dis J 1998;17:1126-31.
  32. Lieberthal AS, Carroll AE, Chonmaitree T, et al.  The diagnosis and management of acute otitis media.  Pediatrics 2013;131:e964–e99.
  33. Little P, Gould C, Moore M, et al.  Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trial.  BMJ 2002;325:22-5.
  34. Little P, Gould C, Williamson I, et al.  Pragmatic randomized controlled trial of two prescribing strategies for childhood acute otitis media.  BMJ 2001;322:336-42.
  35. Mandel EM, Casselbrant ML.  Recent developments in the treatment of otitis media with effusion.  Drugs 2006;66:1565-76.
  36. Marchisio P, Principi N, Sala E, et al.  Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children.  Antimicrob Agents Chemother 1996;40:2732-6.
  37. McIsaac WJ, Coyte PC, Croxford R, et al.  Otolaryngologists’ perceptions of the indications for tympanostomy tube insertion in children.  CMAJ 2000;162:1285-8.
  38. Paradise JL, Feldman HM, Campbell TF, et al.  Tympanostomy tubes and developmental outcomes at 9 to 11 years of age.  N Engl J Med 2007;356:248-61.
  39. Schloss MD.  Otitis media: to treat or not to treat?  Can Respir J 1999;6:51-3A.
  40. Simor AE, Louie M, The Canadian Bacterial Surveillance Network, and Low DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:2190-3.
  41. Spiro DM, Arnold DH.  The concept and practice of a wait-and-see approach to acute otitis media.  Curr Opin Peds 2008;20:72-8.
  42. Tahtinen PA, Laine MK, Huovinen P, et al.  A placebo-controlled trial of antimicrobial treatment for acute otitis media.  N Engl J Med 2011;364:116-26.
  43. Trujillo M, Correa N, Olsen K, et al.  Cefprozil concentrations in middle ear fluid of children with acute otitis media.  Pediatr Infect Dis J 2000;19:268-70.
  44. Uhari M, Mantysaari K, Niemela M.  A meta-analytic review of the risk factors for acute otitis media.  Clin Infect Dis 1996;22:1079-83.
  45. Vouloumanou EK, Karageorgopoulos DE, Kazantzi MS, et al.  Antibiotics versus placebo or watchful waiting for acute otitis media:  a meta-analysis of randomized controlled trials.  J Antimicrob Chemother 2009;64:16-24.
  46. Wall GM, Stroman DW, Roland PS, et al.  Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections.  Ped Infect Dis J 2009;28:141-4.   

Otitis Externa

  1. Dohar JE.  Evolution of management approaches for otitis externa.  Ped Infect Dis J 2003;22:299-308.
  2. Wooltorton E.  Ototoxic effects from gentamicin ear drops.  Can Med Assoc J 2002;167:56. 

Sinusitis

  1. Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al.  Antibiotics for acute maxillary sinusitis.  Cochrane Database Syst Rev 2008:2:CD000243.
  2. Alberta Medical Association.  Diagnosis and management of acute bacterial sinusitis.  Edmonton (AB):  Toward Optimized Practice;2008.
  3. Bachert C, Fokkens W, Lund V, et al.  Medical management of rhinosinusitis.  Respirology & Allergy Scientific Update 2004;June.
  4. Boucher FD.  The new macrolide antibiotics: use them carefully.  Paediatr Child Health 1997;2:385-6.
  5. Brook I, Gooch WM, Jenkins SG, et al.  Medical management of acute bacterial sinusitis.  Recommendations of a clinical advisory committee on pediatric and adult sinusitis.  Ann Otol Rhinol Laryngol 2000;109:1-20.
  6. Chow AW, Benninger MS, Brook I, et al.  IDSA clinical practice guidelines for acute bacterial rhinosinusitis in children and adults.  Clin Infect Dis 2012;54:e72-112.
  7. Consensus statement: summary diagnostic and therapeutic recommendations for sinusitis.  Hosp Med Suppl 1997;33:54-5.
  8. de Bock GH, Dekker FW, Stolk J, Springer MP, Kievit J, van Houwelingen JC.  Antimicrobial treatment in acute maxillary sinusitis:  a meta-analysis.  J Clin Epidemiol 1997;50:881-90.
  9. DeMuri GP, Wald ER.  Complications of acute bacterial sinusitis in children.  Ped Infect Dis J 2011:30;701-2.
  10. Desrosiers M, Evans GA, Keith PK, et al.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.  Allergy Asthma Clin Immunol 2011;7:2.
  11. Desrosiers M, Frenkiel S, Hamid QA, et al.  Acute bacterial sinusitis in adults:  management in the primary care setting.  J Otololaryngol 2002;31(suppl 2):2S2-14.
  12. Dykewicz MS, Hamilos DL.  Rhinitis and simusitis.  J Allergy Clin Immunol 2010;125:103-15.
  13. Evans KL.  Recognition and management of sinusitis.  Drugs 1998;56:59-71.
  14. Falagas ME, Giannopoulu KP, Vardakas KZ, et al.  Comparison of antibiotics with placebo for treatment of acute sinusitis:  a meta-analysis of randomized controlled trials.  Lancet 2008;8:543-52.
  15. Falagas ME, Karageorgopoulos DE, Grammatikkos AP, et al.  Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis:  a meta-analysis of randomized trials.  Br J Clin Pharmacol 2009;67:161-71.
  16. Frenkiel S.  Diagnosis and management of sinusitis.  Can J Diagn 1998;Fall:2-7.
  17. Garbutt JM, Banister C, Spitznagel E, et al.  Amoxicillin for acute rhinosinusitis.  JAMA 2012:307;685-92.
  18. Garbutt JM, Goldstein M, Gellman E, et al. A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis.  Pediatrics 2001;107:619-25.
  19. George DL, Falk PS, Meduri GU, et al.  Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study.  Clin Infect Dis 1998;27:463-70.
  20. Gwaltney JM.  Acute community acquired bacterial sinusitis: to treat or not to treat.  Can Respir J 1999;6:46-50.
  21. Gwaltney JM.  Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-25.
  22. Hayward G, Heneghan C, Perera R, et al.  Intranasal corticosteroids in management of acute sinusitis:  a systematic review and meta-analysis.  Ann Fam Med 2012;10:241-9.
  23. Hickner JM, Bartlett JG, Besser RE, et al.  Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background.  Ann Intern Med 2001;134:498-505.
  24. Institute for Clinical Systems Integration.  Acute sinusitis in adults.  Postgrad Med 1998;103:154-68.
  25. Loannidis JPA, Lau J.  Technical report:  evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children:  a systematic overview.  Pediatrics 2001;108:e57.
  26. Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al.  Fluoroquinolones compared with β-lactam antibiotics for the treatment of acute bacterial sinusitis:  a meta-analysis of randomized controlled trials.  CMAJ 2008;148:845-54.
  27. Khianey R, Oppenheimer J.  Is nasal saline irrigation all it is cracked up to be?  Ann Allergy Asthma Immunol 2012;109:20-8.
  28. Lemiengre MB, van Driel ML, Merenstein D, et al.  Antibiotics for clinically diagnosed acute rhinosinusitis in adults (review).  Cochrane Database Systematic Reviews 2012, Issue 10. Art. No.: CD006089. DOI: 10.1002/14651858.CD006089.pub4.
  29. Low DE, Desrosiers M, McSherry J, et al.  A practical guide for the diagnosis and treatment of acute sinusitis. Can Med Assoc J 1997;156:S1-14.
  30. Nord CE.  The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 1995;20:1512-24.
  31. Noyek A, Brodovsky D, Coyle S, et al.  Classification, diagnosis and treatment of sinusitis: evidence-based clinical practice guidelines.  Can J Infect Dis 1998;9:3B-24B.
  32. O’Brien KL, Dowell SF, Schwartz B, et al.  Acute sinusitis – principles of judicious use of antimicrobial agents.  Pediatrics 1998;101:174-7.
  33. Orlandi RR, Kingdom TT, Hwang PH.  International consensus statement on allergy and rhinology:  rhinosinusitis executive summary.  Int Forum Allergy Rhinol 2016;6:S3-S21.
  34. Payne SC, Benninger MS.  Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis:  a meta-analysis.  Clin Infect Dis 2007;45:121-7.
  35. Piccirillo JF.  Acute bacterial sinusitis.  N Engl J Med 2004;351:902-10.
  36. Piccirillo JF, Mager DE, Frisse ME, et al.  Impact of first-line vs. second-line antibiotics for the treatment of acute uncomplicated sinusitis.  JAMA 2001;286:1849-56.
  37. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al.  Clinical practice guideline (update):  adult sinusitis.  Otolaryngol Head Neck Surg 2015;152(2S):S1-39.
  38. Rosenfeld RM, Singer M, Jones S.  Systematic review of antimicrobial therapy in patients with acute rhinosinusitis.  Otolaryngol Head Neck Surg 2007;137:32-45.
  39. Pichichero ME.  Short course of antibiotic in acute otitis media and sinusitis infections.  J Int Med Res 2000;28:25A-36A.
  40. Rouby JJ, Laurent P, Gosnach M, et al.  Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Resp Crit Care Med 1994;150:776-83.
  41. Sinus and Allergy Health Partnership.  Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.  Otolaryngol Head Neck Surg 2000;123:S4-31.
  42. Smith MJ.  Evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children:  a systematic review.  Pediatrics 2013;132:e284–e96.
  43. Snow V, Mottur-Pilson C, Hickner JM.  Principles of appropriate antibiotic use for acute sinusitis in adults.  Ann Intern Med 2001;134:495-7.
  44. Stalman W, van Essen GA, van der Graaf Y, et al.  The end of antibiotic treatment in adults with acute sinusitis-like complaints in general practice?  A placebo-controlled double-blind randomized doxycycline trial. Br J Gen Pract 1997;47:794-9.
  45. Stein M, Caplan ES.  Nosocomial sinusitis:  a unique subset of sinusitis.  Curr Opin Infect Dis 2005;18:147-50.
  46. Talmor M, Li P, Barie PS.  Acute paranasal sinusitis in critically ill patients: guidelines for prevention, diagnosis, and treatment.  Clin Infect Dis 1997;25:1441-6.
  47. Tan B.  Acute sinusitis in children.  Paediatr Child Health 1997;2:314-6.
  48. Taverner D, Latte J.  Nasal decongestants for the common cold.  Cochrane Database Syst Rev 2007;1:CD001953.
  49. Van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, et al.  Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis.  Lancet 1997;349:683-7.
  50. Venekamp RP, Bonten MJM, Rovers MM, et al.  Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis:  a randomized controlled trial.  CMAJ 2012:184:e7517.
  51. Venekamp RP, Thompson MJ, Hayward G, et al.  Systemic corticosteroids for acute sinusitis.  Cochrane Database Systematic Reviews 2011, Issue 12. Art. No.: CD008115. DOI: 10.1002/14651858.CD008115.pub2.
  52. Wald ER, Bordley WC, Darrow DH, et al.  American Academy of Pediatrics clinical practice guideline: management of sinusitis. Pediatrics 2001;108:798-808.
  53. Westergren V, Lundblad L, Hellquist HB, et al.  Ventilator-associated sinusitis: a review.  Clin Infect Dis 1998;27:851-64.
  54. Williamson IG, Rumsby K, Benge S, et al.  Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis.  JAMA 2007;298:2487-96.
  55. Williams Jr JW, Aguilar C, Makela M, et al.  Antibiotics for acute maxillary sinusitis (Cochrane Review).  In:  The Cochrane Library, Issue 4, 2001.  Oxford:  Update Software.
  56. Wilson JF.  Acute sinusitis.  Ann Intern Med 2010.
  57. Young J, De Sutter A, Merenstein D, et al.  Antibiotics for adults with clinically diagnosed acute rhinosinusitis:  a meta-analysis of individual patient data.  Lancet 2008;371:908-14.
  58. Zalmanovici A, Yaphe J.  Intranasal steroids for acute sinusitis.  Cochrane Database Syst Rev 2009;4:CD005149.
  59. Zucher DR, Balk E, Engels E, et al. Agency for Health Care Policy and Research Publication No. 99-E016:  Evidence report/technology assessment Number 9. Diagnosis and treatment of acute bacterial rhinosinusitis. www.ahcpr.gov/clinic/sinussum.htm  

Deep Neck space infections

  1. Chow AW.  Deep neck space infections in adults.  UpToDate 2022.
  2. Craig FW, Schunk JE.  Retropharyngeal abscess in children:  clinical presentation, utility of imaging, and current management.  Pediatrics 2003;111:1394-8.
  3. Gilmore WC, Jacobus NV, Gorbach SL, et al.  A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections.  J Oral Maxillofac Surg 1988;46:1065-70.
  4. Kristensen LH, Prag J.  Human necrobacillosis, with emphasis on Lemierre’s Syndrome.  Clin Infect Dis 2000;31:524-32.   

Acute Cervical Adenitis

  1. Margileth AM.  Cervical adenitis.  Pediatr Rev 1985;7:13-24.  

Bronchitis

  1. Anthonisen NR, Manfreda J, Warren CPW, et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.  Ann Intern Med 1987;106:196-204.
  2. Bach PB, Brown C, Gelfand SE, et al.  Management of acute exacerbations of chronic obstructive pulmonary disease:  a summary and appraisal of published evidence. Ann Intern Med 2001;134:600-20.
  3. Bagge K, Sivapalan P, Eklof J, et al.  Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid—data from 43,636 outpatients.  Respir Res 2021;22:11.
  4. Ballow CH, Hyatt JM, Peloquin CA, et al.  Effectiveness of grepafloxacin vs. clarithromycin for bacterial eradication in chronic bronchitis.  Presented at the 36th Annual Meeting of Infectious Diseases Society of America; Denver, CA; Nov. 12-15, 1998. (Abstract 176 Sa)
  5. Balter MS, La Forge J, Low DE, et al.  Canadian guidelines for the management of acute exacerbations of chronic bronchitis.  Can Respir J 2003;10(suppl B):3B-32B.
  6. Chodosh S.  Treatment of acute exacerbations of chronic bronchitis: state of the art.  Am J Med 1991;91:87-92.
  7. Chodosh S.  Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.  Am J Med 1991;91:93-100.
  8. Choi H, McShane PJ, Aliberti S, et al. Bronchiectasis management in adults: state of the art and future directions. Eur Respir J 2024; 63: 2400518 [DOI: 10.1183/13993003.00518-2024].
  9. Daniels JMA, Snijders D, de Graaff CS, et al.  Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med 2010;181:150-7.
  10. Dimopoulos G, Siempos II, Korbila IP, et al.  Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis:  A metaanalysis of randomized controlled trials.  Chest 2007;132:447-55.
  11. Falagas ME, Avgeri SG, Matthaiou DK, et al.  Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis:  a meta-analysis.  J Antimicrob Chemother 2008;62:442-50.
  12. Forward K, Gold R, Gribble M, et al.  Consensus recommendations for management of acute exacerbations of chronic bronchitis.  Can J Diagn 1990;7:129-39.
  13. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background.  Ann Intern Med 2001;134:521-9.
  14. Gonzales R, Sande MA. Uncomplicated acute bronchitis.  Ann Intern Med 2000;133:981-91.
  15. Grayston JT, Aldous MB, Easton A, et al.  Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.  J Infect Dis 1993;168:1231-5.
  16. Grossman R.  Respiratory tract infections: therapeutic considerations.  Can J Diagn 1999;Winter:2-7.
  17. Grossman RF.  Management of acute exacerbation of chronic bronchitis.  Can Respir J 1999;6:40-5.
  18. Ho PL, Tse WS, Tsang KWT, et al.  Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae:  a case-control study.  Clin Infect Dis 2001;32:701-7.
  19. Ilowite J, Spiegler P, Chawla S.  Bronchiectasis:  new findings in the pathogenesis and treatment of this desease.  Curr Opin Infect Dis 2008;21:163-7.
  20. Irwin RS, Madison JM.  The diagnosis and treatment of cough.  New Engl J Med 2000;343:1715-21.
  21. Madaras-Kelly KJ, Magdanz SB, Johnson CK, et al.  Clinical outcome of ambulatory acute exacerbations of chronic bronchitis with older versus newer antimicrobials.  Ann Pharmacother 2002;36:975-80.
  22. O’Brien KL, Dowell SF, Schwartz B, et al.  Cough illness/bronchitis – principles of judicious use of antimicrobial agents.  Pediatrics 1998;178-81.
  23. Orr PH, Scherer K, Macdonald A, et al.  Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature.  J Fam Pract 1993;36:507-12.
  24. Pauwels RA, Buist AS, Calverley PMA, et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med 2001;163:1256-76.
  25. Quon BS, Qi Gan W, Sin DD.  Contemporary management of acute exacerbations of COPD:  A systematic review and metaanalysis.  Chest 2008;133:756-66.
  26. Rizkallah J, Man SFP, Sin DD.  Prevalence of pulmonary embolism in acute exacerbations of COPD:  A systematic review and metaanalysis.  Chest 2009;135:786-93.
  27. Russo RL, D'Aprile M.  Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Pharmacother 2001;35:576-81.
  28. Saint S, Bent S, Vittinghoff E, et al.  Antibiotics in chronic obstructive pulmonary disease exacerbations.  A meta-analysis.  JAMA 1995;273:957-60.
  29. Sethi S, Murphy TF.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease.  N Engl J Med 2008;359:2355-65.
  30. Smucny J, Fahey T, Becker L, et al.  Antibiotics for acute bronchitis.  Cochrane Database of Systematic Reviews 200;4:CD000245.
  31. Snow V, Lascher S, Mottur-Pilson C.  Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001;134:595-9.
  32. Snow V, Mottur-Pilson C, Gonzales R.  Principles of appropriate antibiotic use for treatment of acute bronchitis in adults.  Ann Intern Med 2001;134:518-20.
  33. Stolbrink M, Bonnett LJ, Blakey JD.  Antibiotics for COPD exacerbations:  does drug or duration matter?  A primary care database analysis.  BMJ Open Resp Res 2019;6:e000458. doi:10.1136/bmjresp-2019-000458.
  34. Verghese A, Ismail HM.  Acute exacerbations of chronic bronchitis.  Postgrad Med 1994;96:75-89.
  35. Wenzel RP, Fowler AA.  Acute Bronchitis.  N Eng J Med 2006;355-:2125-30.   

Bronchiolitis

  1. Subcommittee on the Diagnosis and Management of Bronchiolitis.  Diagnosis and management of bronchiolitis.  www.pediatrics.org/cgi/dol/10.1542/peds.2006-2223.
  2. Tregoning JS, Schwarze J.  Respiratory viral infections in infants:  causes, clinical symptoms, virology, and immunology.  Clin Microb Rev 2010:74-98.
  3. Zorc JJ, Hall CB.  Bronchiolitis:  recent evidence on diagnosis and management.  Pediatrics 2010;125:342-9.  

Pneumonia

  1. Ailani RK, Agastya G, Ailani RK, et al.  Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia.  Arch Intern Med 1999;159:266-70.
  2. Alberta Medical Association.  Guideline for the diagnosis and management of community-acquired pneumonia:  Adult.  Feb 2002.
  3. Alberta Medical Association.  Guideline for the diagnosis and management of community-acquired pneumonia: Pediatric.  Jan 2002. 
  4. Alberta Medical Association.  Guideline for the diagnosis and management of nursing home acquired pneumonia.  Sep 2002.
  5. American Thoracic Society.  Guidelines for the management of adults with community -acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
  6. Bartlett JG, Mundy LM.  Community-acquired pneumonia. N Engl J Med 1995;333:1618-24.
  7. Baselski VS, Wunderink RG.  Bronchoscopic diagnosis of pneumonia.  Clin Microbiol Rev 1994;7:533-58.
  8. Battleman DS, Callahan M, Thaler HT.  Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia.  Arch Intern Med 2002;162:682-8.
  9. Bielicki JA, Stohr W, Barratt S, et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment of children with community-acquired pneumonia.  The CAP-IT randomized clinical trial.  JAMA 2021;326:1713-24.
  10. Boucher FD.  The new macrolide antibiotics: use them carefully.  Paediatr Child Health 1997;2:385-6.
  11. Bradley JS.  Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines.  Pediatr Infect Dis J 2002;21:592-8.
  12. Bradley JS, Byington CL, Shah SS, et al.  The management of community-acquired pneumonia in infants and children older than 3 months of age:  clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.  Clin Infect Dis 2011.
  13. British Thoracic Society Standards of Care Committee.  BTS guidelines for the management of community acquired pneumonia in adults.  Thorax 2001;56 Suppl 4:IV 1-64.
  14. Chiou CC.  Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance?  Clin Infect Dis 2006;42:234-7.
  15. Confalonieri M, Urbino R, Potena A, et al.  Hydrocortisone infusion for severe community-acquired pneumonia.  A preliminary randomized study.  Am J Respir Crit Care Med 2005;171:242-8.
  16. Cunha BA.  Doxycycline for community-acquired pneumonia. Clin Infect Dis 2003;37:870.
  17. Davies HD. Community-acquired pneumonia in children.  Paediatrics & Child Health 2003;8:616-9.
  18. Dinh A, Ropers J, Duran C, et al.  Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.  Lancet 2021;397:1195-203.
  19. Dunbar LM, Wunderink RG, Habib MP, et al.  High-dose, short-course levofloxacin for community-acquired pneumonia:  a new treatment paradigm.  Clin Infect Dis 2003;37:752-60.
  20. el Moussaoui R, de Borgie C, van den Broek P, et al.  Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.  BMJ 2006;332:1355.
  21. el-Solh AA.  Nursing home acquired pneumonia:  approach to management.  Curr Opin Infect Dis 2011:24;148-151.
  22. el Solh AA, Alhajhusain A.  Update on the treatment of Pseudomonas aeruginosa pneumonia.  J Antimicrob Chemother 2009;64:229-38.
  23. Fang GD, Fine M, Orloff J, et al.  New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990;69:307-16.
  24. Finch RG, Woodhead MA.  Practical considerations and guidelines for the management of community-acquired pneumonia.  Drugs 1998;55:31-45.
  25. Fine MJ, Auble TE, Yealy DM, et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia.  N Engl J Med 1997;336:243-50.
  26. Furlan L, Erba L, Trombetta L, et al.  Short‑ vs long‑course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign.  Internal Emerg Med 2019;14:377-94.
  27. Garau J.  Clinical implications of resistance in the management of respiratory tract infections.  Can Respir J 1999;6:23-6.
  28. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia:  An observational, multicenter study comparing monotherapy with combination antibiotic therapy.  Crit Care Med 2007;35:1888-95.
  29. Garot D, Respaud R, Lanotte P, et al.  Population pharmacokinetics of ceftriaxone in critically ill septic patients:  a reappraisal.  Br J Clin Pharmacol 2011;72:5:758-67.
  30. Goldstein RA, Rohatgi PK, Bergofsky EH, et al.  Clinical role of bronchoalveolar lavage in adults with pulmonary disease.  Am Rev Respir Dis 1990;142:481-6.
  31. Gorman SK, Slavik RS, Marin J.  Corticosteroid treatment of severe community-acquired pneumonia.  Ann Pharmacother 2007;41:1233-7.
  32. Guz D, McNeil R, Buchrits S, et al.  Ceftriaxone 1 g versus 2 g per day, for the treatment of community‑acquired pneumonia: a retrospective cohort study.  Intern Emerg Med 2023 https://doi.org/10.1007/s11739-023-03372-y.
  33. Han LL, Alexander JP, Anderson LJ.  Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden.  J Infect Dis 1999;179:25-30.
  34. Health Quality Ontario.  Severity assessment tools for patients with community-acquired pneumonia:  a rapid review.  Toronto, Ontario; Nov 2013;1-27.  Available from: https://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/rapid-reviews.
  35. Heffelfinger JD, Dowell SF, Jorgensen JH, et al.  Management of community-acquired pneumonia in the era of pneumococcal resistance.  Arch Intern Med 2000;160:1399-1408.
  36. High KP, Bradley SF, Gravenstein S, et al.  Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities:  2008 update by the Infectious Diseases Society of America.  Clin Infect Dis 2009:48;149-71.
  37. Hoban DJ, Karlowsky JA, Zhanel GG, et al.  Evolving patterns of resistance to respiratory pathogens in Canada.  Can Respir J 1999;6:27-30.
  38. Horita N, Otsuka T, Haranaga S, et al.  Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia:  A systematic review and meta-analysis.  Respirology 2016;21:1193-1200.
  39. Houck PM, Bratzler DW, Nsa W, et al.  Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.  Arch Intern Med 2004;164:637-44.
  40. Jadavji T, Law B, Lebel MH, et al.  A practical guide for the diagnosis and treatment of pediatric pneumonia.  Can Med Assoc J 1997;156:S703-11.
  41. Jain S, Self H, Wunderink RG, et al.  Community-acquired pneumonia requiring hospitalization among U.S. adults.  N Engl J Med 2015;373:415-27.
  42. Jasper AS, Musuuza JS, Tischendorf JS, et al.  Are fluoroquinolones or macrolides better for treating legionella pneumonia? A systematic review and meta-analysis.  Clin Infect Dis 2021;72:1979–89. https://doi.org/10.1093/cid/ciaa441
  43. Johnson JR.  Doxycycline for the treatment of community-acquired pneumonia. Clin Infect Dis 2002;35:632.  
  44. Jones BE, Ying J, Stevens V, et al.  Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia.  JAMA Intern Med 2020;180:552-60.
  45. Jones RN, Sader HS, Fritsche TR.  Doxycycline use for community-acquired pneumonia:  contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).  Diagn Microbiol Infect Dis 2004;49:147-9.
  46. Laheij RJ, Sturkenboom MCJM, Hassing RJ, et al.  Risk of community-aquired pneumonia and use of gastric acid-suppressive drugs.  JAMA 2004;292:1955-60.
  47. Le Saux N, Robinson JL.  Pneumonia in healthy Canadian children and youth:  Practice points for management.  Paed Child Health 2011;16:417-20.
  48. Le Saux N, Robinson J.  Popularization of "10".  J Med Microbiol Infect Dis 2021;6:173-6.
  49. Le Saux N, Robinson JL.  Uncomplicated pneumonia in healthy Canadian children and youth:  practice points for management.  Paediatr Child Health 2015;20:441-5.
  50. Lee JS, Giesler DL, Gellad WF, et al.  Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review.  JAMA 2016;315:593-602.
  51. Lim WS, vander Eerden MM, Laing R, et al.  Defining community acquired pneumonia severity on presentation to hospital:  an international derivation and validation study.  Thorax 2003;58:377-82.
  52. Lynch JP, Martinez FJ.  Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.  Clin Infect Dis 2002;34(suppl 1):S27-46.
  53. Kollef MH, Morrow LE, Baughman RP, et al.  Health care-associated pneumonia (HCAP):  a critical appraisal to improve identification, management, and outcomes - proceedings of the HCAP Summit.  Clin Infect Dis 2008:46;296-334.
  54. MacFarlane JT, Colville A, Guion A, et al.  Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community.  Lancet 1993;341:511-4.
  55. Mandell LA, Bartlett JG, Dowell SF, et al.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.  Clin Infect Dis 2003;37:1405-33.
  56. Mandell LA, Marrie TJ, Grossman RF, et al.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.  Clin Infect Dis 2000;31:383-421.
  57. Mandell LA, Wunderink RG, Anzueto A, et al.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.  Clin Infect Dis 2007;44:27-72.
  58. Marrie TJ, Lau CY, Wheeler SL, et al.  A controlled trial of a critical pathway for treatment of community-acquired pneumonia.  JAMA 2000;283;749-55.
  59. Marrie TJ.  Risks and outcomes in community acquired pneumonia.  Can Respir J 1999;6:6-9.
  60. Marrie TJ.  Community-acquired pneumonia in the elderly. Clin Infect Dis 2000;31:1066-78.
  61. Marrie TJ.  Importance of Streptococcus pneumoniae in community-acquired pneumonia.  Can J Infect Dis 1999;10:19-21.
  62. Martinez FJ.  Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.  Clin Infect Dis 2004;38(suppl 4):S328-40.
  63. Martinez JA, Horcajada JP, Almela M, et al.  Addition of a macrolide to a ß-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis 2003:36;389-95.
  64. McIntosh K.  Community-acquired pneumonia in children.  N Engl J Med 2002;346:429-37.
  65. Meijvis SC, Hardeman H, Remmelts HH, et al.  Dexamethasone and length of hospital stay in patients with community-acquired pneumonia:  a randomised, double-blind, placebo-controlled trial.  Lancet 2011;377:2023-30.
  66. Metlay JP, Waterer GW, Long AC, et al.  Diagnosis and treatment of adults with community-acquired pneumonia; An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America.  2019.  Am J Respir Crit Care Med 2019;200:e45-67.
  67. Mills GD, Oehley MR, Arrol B.  Effectiveness of ß-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia:  meta analysis.  BMJ 2005;330:456-63.
  68. Mylotte JM.  Nursing home-acquired pneumonia.  Clin Infect Dis 2002;35:1205-11.
  69. O’Leary AL, Chan AK, Wattengel BA, et al.  Impact of doxycycline on Clostridioides difficile infection in patients hospitalized with community-acquired pneumonia.  Am J Infect Control 2024;52:280-3.
  70. Peterson LR.  Penicillins for treatment of pneumococcal pneumonia:  does in vitro resistance really matter?  Clin Infect Dis 2006;42:224-33.
  71. Public Health England.  National Institute for Health and Care Excellence (NICE)  guideline - Pneumonia (community acquired): antimicrobial prescribing.  Sep 2019 www.nice.org.uk/guidance/ng138.
  72. Rello J, Rodriguez R, Jubert P, et al.  Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis 1996;23:723-8.
  73. Restrepo MI, Mortensen EM, Anzueto A.  Common medications that increase the risk for developing community-acquired pneumonia.  Curr Opin Infect Dis 2010;23:145-51.
  74. Roord JJ, Wolf BHM, Goossens MMHT, et al.  Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996;40:2765-8.
  75. Santana AR, Amorim FF, Soares FB, et al.  Comparison of CURB-65 and CRB-65 as predictors of death in community-acquired pneumonia in adults admitted to an ICU.  Critical Care 2013, 17(Suppl 3):P39 (doi: 10.1186/cc12655).
  76. Schutze GE, Jacobs RF.  Management of community-acquired bacterial pneumonia in hospitalized children.  Pediatr Infect Dis J 1992;11:160-4.
  77. Shulman ST, Bartlett J, Clyde WA, et al.  The unusual severity of mycoplasmal pneumonia in children with sickle-cell disease.  N Engl J Med 1972;287:164-7.
  78. Talan DA, Moran GJ.  Emergency department management of pneumonia.  Can Respir J 1999;6:10-14.
  79. Tan JS.  Role of ‘atypical’ pneumonia pathogens in respiratory tract infections.  Can Respir J 1999;6:15-9.
  80. Tansarli GS, Mylonakis E.  Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. Antimicrob Agents Chemother 2018;62:1-13.
  81. Telles JP, Cieslinski J, Gasparetto J, et al.  Efficacy of ceftriaxone 1g daily versus 2g daily for the treatment of community-acquired pneumonia:  A systematic review with meta-analysis.  Expert Review Anti-Infective Therapy 2019;17:501-10.
  82. Troy CJ, Peeling RW, Ellis AG, et al.  Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997;277:1214-18.
  83. Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 2016; 176: 1257–65.
  84. Vergis EN, Indorf A, File TM, et al.  Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients.  Arch Intern Med 2000;160:1294-1300.

Aspiration Pneumonia

  1. Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess.  JAMA 1975;234:935-7.
  2. Finegold SM. Aspiration pneumonia. Rev Infect Dis 1991;13:S737-42.
  3. Mandell LA, Niederman MS.  Aspiration pneumonia.  N Engl J Med 2019;380:651-63.
  4. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344:665-71.

Nosocomial Pneumonia

  1. Bartlett JG, O’Keefe P, Tally FP, et al.  Bacteriology of hospital-acquired pneumonia.  Arch Intern Med 1986;146:868-71.
  2. Burgess DS.  Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections.  Clin Infect Dis 2005;40:S99-104.
  3. Cunha BA. The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Med Clin North Am 1995;79:581-97.
  4. Ferguson ND, Grossman RF. Hospital-acquired pneumonia:fighting the germs. Can J Diagnosis 1997;Feb:95-108.
  5. Fiel S.  Guidelines and critical pathways for severe hospital-acquired pneumonia.  Chest 2001;119(2 suppl):412S-18S.
  6. Garau J, Bouza E, Chastre J, et al.  Management of methicillin-resistant Staphylococcus aureus infections.  Clin Microbiol Infect 2009:15;125-136.
  7. Gotfried MH, Danzinger LH, Rodvold KA.  Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.  Chest 2001;119:1114-22.
  8. Haque NZ, Zuniga LC, Peyrani P, et al.  Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia.  Chest 2010 138:1356-62.
  9. Kalil A, Metersky M, Klompas M, et al.  Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.  Clin Infect Dis 2016;63(5):575–82.
  10. Kalil AC, Murthy MH, Hermsen ED, et al.  Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia:  a systematic review and meta-analysis.  Crit Care Med 2010:38;1802-8.
  11. Lynch JP.  Hospital-acquired pneumonia.  Risk factors, microbiology, and treatment. Chest 2001;119(2 suppl):373S-84S.
  12. Mallow S, Rebuck JA, Osler T, et al.  Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?  Curr Surg 2004:61;452-8.
  13. Mandell LA, Marrie TJ, Niederman MS. The Canadian Hospital Acquired Pneumonia Consensus Conference Group. Initial antimicrobial treatment of hospital acquired pneumonia in adults: a conference report. Can J Infect Dis 1993;4:317-21.
  14. Masterton RG, Galloway A, French G, et al.  Guidelines for the management of hospital-acquired pneumonia in the UK:  report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.  J Antimicrob Chemo 2008:62;5-34.
  15. Rotstein C, Evans G, Born A, et al.  Clinical practice guidelines for hosptal-acquired pneumonia and ventilator-associated pneumonia in adults.  Can J Infect Dis Med Microbiol 2008;19:19-53.
  16. Rubinstein E, Kollef MH, Nathwani D.  Pneumonia caused by methicillin-resistant Staphylococcus aureus.  Clin Infect Dis 2008:46;378-85.
  17. Scheld WM, Mandell GL. Nosocomial pneumonia:pathogenesis and recent advances in diagnosis and therapy. Rev Infect Dis 1991;13:S743-51.
  18. Tobin MJ, Grenvik A.  Nosocomial lung infection and its diagnosis.  Crit Care Med 1984;12:191-7.
  19. Torres A, Niederman M, Chastre J, et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia.  Eur Respir J 2017;50:1700582.
  20. Torres A, Rello J.  Update in community-acquired and nosocomial pneumonia 2009.  Am J Respir Crit Care Med 2010;181;782-7.
  21. Unertl KE, Lenhart FP, Forst H, et al. Systemic antibiotic treatment of nosocomial pneumonia. Intensive Care Med 1992;18:S28-34.
  22. West M, Boulanger BR, Fogarty C, et al.  Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia:  a multicenter, prospective, randomized, open-label study.  Clin Ther 2003;25:485-506.
  23. Wunderink RG, Niederman MS, Kollef MH, et al.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia:  a randomized, controlled study.  Clin Infect Dis 2012

Ventilator-Associated Pneumonia

  1. Albin OR, Kaye KS, McCreary EK, et al.  Less is more? Antibiotic treatment duration in Pseudomonas aeruginosa ventilator-associated pneumonia.  Clin Infect Dis 2022. 
  2. American Thoracic Society.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med 2005;171:388-416.
  3. Barcenilla F, Gasco E, Rello J, et al.  Antibacterial treatment of invasive mechanical ventilation – associated pneumonia.  Drugs & Aging 2001;18:189-200.
  4. Bougle A, Tuffet S, Federici L, et al.  Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial.  Intensive Care Med 2022;48:841-9.
  5. Chastre J, Wolff M, Fagon JY, et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults.  A randomized trial.  JAMA 2003;290:2588-98.
  6. Kalil A, Metersky M, Klompas M, et al.  Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63(5):575–82.
  7. Koenig SM, Truwit JD.  Ventilator-associated pneumonia:  diagnosis, treatment, and prevention.  Clin Microb Rev 2006:19;637-57.
  8. Kollef MH.  The prevention of ventilator-associated pneumonia.  N Engl J Med 1999;340;627:34.
  9. Kollef MH.   Ventilator-associated pneumonia:  the importance of initial empiric antibiotic selection.  Infect Med 2000;17:265-8, 278-83.
  10. McQuillen DP, Duncan RA, Craven DE.  Ventilator-associated pneumonia:  emerging principles of management.  Infect Med 2005;22:104-18.
  11. Mo Y, Booraphun S, Yunkai Li A, et al.  Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial.  Lancet Respir Med 2024;12:399–408.
  12. Morehead RS, Pinto SJ.  Ventilator-associated pneumonia.  Arch Intern Med 2000;160:1926-36.
  13. Muscedere J, Dodek P, Keenan S, et al.  Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia:  diagnosis and treatment.  J Crit Care 2008:23;138-47.
  14. Muscedere J, Dodek P, Keenan S, et al.  Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia:  prevention.  J Crit Care 2008:23;126-37.
  15. Principi N, Esposito S.  Ventilator-associated pneumonia (VAP) in pediatric intensive care units.  Pediatr Infect Dis J 2007:26;841-44. 
  16. Torres A, Niederman M, Chastre J, et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia.  Eur Respir J 2017;50:1700582.

Cystic fibrosis

  1. Burkhardt O, Lehmann C, Madabushi R, et al.  Once-daily tobramycin in cystic fibrosis:  better for clinical outcome than thrice-daily tobramycin but more resistance development?  J Antimicrob Chemother 2006;58:822-9.
  2. Coulthard KP, Peckham DG, Conway SP, et al.  Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis - caution with trough concentrations.  J Cystic Fibrosis 2007;6:125-30.
  3. Touw DJ, Knox AJ, Smyth A.  Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis.  J Cystic Fibrosis 2007;6:327-33.

Influenza

  1. Anon.  Antiviral agents for the treatment and chemoprophylaxis of influenza.  MMWR 2011:60.
  2. Anon.  Antiviral drugs for prophylaxis and treatment of influenza.  Med Lett Drugs Ther 2005;47:93-5.
  3. Anon.  Policy statemenet - recommendations for prevention and control of influenza in children, 2010-2011.  Am Ac Peds.
  4. Aoki FY, Allen DU, Stiver HG, et al.  The use of antiviral drugs for influenza:  guidance for practitioners, 2010-11.
  5. Jefferson T, Jones M, Doshi P, et al.  Neuraminidase inhibitors for preventing and treating influenza in healthy adults:  systematic review and meta-analysis.  BMJ 2009:339;1-8.
  6. Smith JR, Ariano RE, Toovey S.  The use of antiviral agents for the management of severe influenza.  Crit Care Med 2010:38;43-51.
  7. Uyeki TM, Bernstein HH, Bradley JS, et al.  Clinical practice guidelines by the Infectious Diseases Society of America:  2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza.  Clin Infect Dis 2019;68:1-47.

Lung abscess

  1. Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993;16:S248-55.
  2. Bartlett JG, Gorbach SL. Penicillin or clindamycin for primary lung abscess? Ann Intern Med 1983;98:546-8.
  3. Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess. JAMA 1975;234:935-7.
  4. Gadkowski LB, Stout JE.  Cavitary pulmonary disease.  Clin Microb Rev 2008:21;305-33.
  5. Gudiol F, Manresa F, Pallares R, et al. Clindamycin vs penicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990;150:2525-9.
  6. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983;98:466-71.
  7. Marina M, Strong CA, Civen R, et al.  Bacteriology of anaerobic pleuropulmonary infections:  preliminary report.  Clin Infect Dis 1993;16:256-62.
  8. Perlino CA. Metronidazole vs clindamycin treatment of anaerobic pulmonary infection: failure of metronidazole therapy. Arch Intern Med 1981;141:1424-7.
  9. Yazbeck MF, Dahdel M, Kalra A, et al.  Lung abscess:  update on microbiology and management.  Am J Therapeut 2012.

Empyema

  1. Bryant RE, Salmon CJ. Pleural empyema. Clin Infect Dis 1996;22:747-64.
  2. Heffner J.  Multicenter trials of treatment for empyema – after all these years.  New Engl J Med 2005;352:926-28.
  3. Koegelenberg CFN, Diacon AH, Bolliger CT.  Parapneumonic pleural effusion and empyema.  Respiration 2008:75;241-50.
  4. Maskell NA, Davies CWH, Nunn AJ, et al.  U.K. controlled trial of intrapleural streptokinase for pleural infection.  N Engl J Med 2005;352:865-74.
  5. Misthos P, Sepsas E, Konstantinou M, et al.  Early use of intrapleural fibrinolytics in the management of postpneumonic empyema.  A prospective study.  Europ J Cardio-Thor Surg 2005;28:599-603.
  6. Rahman NM, Chapman SJ, Davies RJO.  The approach to the patient with a parapneumonic effusion.  Clin Chest Med 2006:27;253-66.
  7. Sahn SA.  Diagnosis and management of parapneumonic effusions and empyema.  Clin Infect Dis 2007:45;1480-6.
  8. Schiza S, Siafakas NM.  Clinical presentation and management of empyema, lung abscess and pleural effusion.  Curr Opin Pulm Med 2006:12;205-12.

Tuberculosis

  1. Anon.  Active tuberculosis:  diagnosis and management guideline.
  2. Anon.  Treatment guidelines:  drugs for tuberculosis.  2009:7.
  3. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America:  Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. Reprinted in: Morb Mortal Weekly Rep 2003;52(No. RR-11):1-77. https://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf
  4. Canadian Thoracic Society (CTS) of the Canadian Lung Association (CLA) and the Public Health Agency of Canada (PHAC).  Canadian Tuberculosis Standards, 7th Edition, 2013. https://www.respiratoryguidelines.ca/tb-standards-2013
  5. Cooper R, Houston S, Hughes C, et al. Chapter 10: Treatment of active tuberculosis in special populations. Can J Resp Crit Care Sleep Med 2022;6(sup1): 149–66. https://doi.org/10.1080/24745332.2022.2039500
  6. Dooley KE, Golub J, Goes FS, et al.  Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.  Clin Infect Dis 2002:34:1607-12.
  7. Horsburgh Jr CR, Feldman S, Ridzon R.  Practice guidelines for the treatment of tuberculosis.  Clin Infect Dis 2000; 31: 633-9
  8. Johnston JC, Cooper R, Menzies D. Chapter 5: Treatment of tuberculosis disease. Can J Resp Crit Care Sleep Med 2022;6(sup1):66–76. https://doi.org/10.1080/24745332.2022.2036504 
  9. Long R, Ellis E.  Introducing the sixth edition of the Canadian Tuberculosis Standards.  Can J Infect Dis Med Microbiol 2007:18;283.

  10. Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:559–70. https://doi.org/10.1136/thx.2009.133173

  11. Nahid P, Dorman SE, Alipanah N, et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016;63; 853–67. https://doi.org/10.1093/cid/ciw566

  12. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Resp Crit Care Med 2019;200(10). https://doi.org/10.1164/rccm.201909-1874st

  13. Small PM, Fujiwara PI.  Management of tuberculosis in the United States.  N Engl J Med 2001;345:189-200.
  14. Treatment of tuberculosis.  National Guideline Clearinghouse 2004.
Content Version: 1.1.1151 Oct 31, 2024.06:09
©1998-2020 Alberta Health Services